Why Novo Nordisk is dropping its collaboration with Hims & Hers

Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.

Editor's Pick

Top Story Why Novo Nordisk Is Dropping Its Collaboration with Hims & Hers Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s. Sponsored From Data Silos to Integrated Care: Driving Provider Engagement Presented by Veradigm Explore how integrated workflow solutions—powered by Veradigm's suite of products—can transform your operations into a more efficient, connected healthcare system. ▶️ Get started today! Apply to Pitch at INVEST Digital Health 2025 in Dallas Are you redefining healthcare operations with AI? We're looking for the next wave of digital health startups using artificial intelligence to transform the day-to-day work of providers. If your solution streamlines diagnosis, clinical documentation, scheduling, or patient engagement, this is your moment to shine. Click here to learn more and apply.

Featured News

Hackers Use AI to Amplify Email Security Threats to Healthcare [Sponsored] A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats. The Hospital Word Has Become a Tale of the Haves and Have-Nots Health system performance has splintered into three distinct groups — leaders, strugglers and those stuck in the middle, according to Fitch Ratings' Kevin Holloran. At the HFMA Annual Conference, he and Mayo Clinic CFO Dennis Dahlen discussed how technology and innovation are accelerating this divide. Nektar's Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear Nektar Therapeutics' biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis. How Smarter Metrics Can Unlock AI's Potential in Healthcare Healthcare doesn't reward shortcuts. It rewards outcomes. AI will play a critical role in shaping those outcomes — but only if leaders measure what truly matters. The best AI implementations elevate expertise, improve quality and create space for innovation. What the New CMS Strategy Signals for Rehab Professionals The CMS vision is ambitious, but so is the potential for rehab therapy to shape its execution. To do that, providers must actively engage, document their impact, and advocate for their inclusion in evolving models of care.

Video   Why Capping Hospital Rate Increases Doesn't Lower Employer Insurance Premiums At the HMFA Annual Conference in Denver, Rod Hanners, CEO of Keck Medicine of USC, said that efforts to limit hospital rate increases aren't reducing employer insurance premiums, as intended.

Sponsored Navina's AI Copilot Eases the Value-Based Burden, Study Shows Presented by Navina A new independent study from Phyx Primary Care's Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices. Learn More

Resources

MedCity Pivot: How Veradigm Aims to Close the Information Gap Megan Zakrewsky, vice president of product at Veradigm talks about how the company is utilizing tech among providers, payers and patients. Watch now!

MedCity News • PO Box 901 • New York, NY unsubscribe